CAMP4 Therapeutics (NASDAQ:CAMP) Director Sells $1,616,000.00 in Stock

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Director Andrew Schwab sold 400,000 shares of the business’s stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $4.04, for a total transaction of $1,616,000.00. Following the completion of the transaction, the director directly owned 2,033,270 shares in the company, valued at $8,214,410.80. This trade represents a 16.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

CAMP4 Therapeutics Stock Performance

NASDAQ CAMP opened at $3.80 on Thursday. The company has a market capitalization of $238.45 million, a PE ratio of -1.64 and a beta of 0.27. CAMP4 Therapeutics Corporation has a 52-week low of $1.41 and a 52-week high of $7.75. The company has a 50-day simple moving average of $4.11 and a 200 day simple moving average of $4.34.

CAMP4 Therapeutics (NASDAQ:CAMP) last released its earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). The company had revenue of $1.78 million for the quarter. CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. As a group, analysts forecast that CAMP4 Therapeutics Corporation will post -0.57 EPS for the current fiscal year.

Hedge Funds Weigh In On CAMP4 Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bridgeway Capital Management LLC purchased a new stake in shares of CAMP4 Therapeutics in the 2nd quarter valued at about $36,000. Jefferies Financial Group Inc. purchased a new stake in CAMP4 Therapeutics in the fourth quarter valued at approximately $70,000. Bank of America Corp DE purchased a new stake in CAMP4 Therapeutics in the second quarter valued at approximately $78,000. OMERS ADMINISTRATION Corp bought a new stake in CAMP4 Therapeutics during the fourth quarter valued at approximately $115,000. Finally, Goldman Sachs Group Inc. bought a new stake in CAMP4 Therapeutics during the fourth quarter valued at approximately $115,000.

Analyst Ratings Changes

A number of brokerages recently issued reports on CAMP. Zacks Research upgraded CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, August 17th. Chardan Capital set a $6.50 price target on shares of CAMP4 Therapeutics and gave the company a “buy” rating in a research note on Wednesday, June 10th. Piper Sandler reissued an “overweight” rating and set a $15.00 target price (up from $12.00) on shares of CAMP4 Therapeutics in a report on Friday, August 14th. Weiss Ratings upgraded CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 14th. Finally, JPMorgan Chase & Co. raised CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $5.00 to $9.00 in a report on Tuesday, June 16th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, CAMP4 Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $9.56.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.